Molecure S.A. is dedicated to finding new treatments for diseases once thought incurable, focusing on small-molecule and mRNA-based drugs. The company is now conducting a Phase II trial of their drug OATD-01 for active pulmonary sarcoidosis.

Mission Therapeutics has initiated a pivotal study on MTX325, which could potentially alter the progression of Parkinson’s Disease.

FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.

Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.

Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.

ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.

Entera Bio Unveils Strong Drug Absorption Results for Innovative Oral GLP-2 Hormone Pill Designed for Individuals with Short Gut Condition.

23andMe Commences Early-Stage Clinical Evaluation of Its Bifunctional Antibody, 23ME-01473, Aimed at ULBP6.

Nurix Unveils the Innovation and Molecular Configuration of Pioneering CBL-B Suppressant NX-1607 during the ACS Conference.

Bristol Myers Squibb Reveals Successful Outcome for CheckMate -9DW Study Assessing the Combination of Opdivo and Yervoy in Extending Survival in Initial Therapy of Progressive Liver Cancer.

The FDA has approved Idorsia's daily drug TRYVIO (aprocitentan), the first to use an endothelin receptor antagonist for managing resistant hypertension alongside other medications.

Mabwell's novel antibody-drug conjugate targeting Nectin-4 in cervical cancer shows significant treatment promise according to initial clinical findings.